Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson To Host Investor Conference Call on Phase 3 COVID-19 Vaccine Results Transcript

Jan 29, 2021 / 02:00PM GMT
Release Date Price: R$59.7 (-2.78%)
Operator

Good morning, and welcome to Johnson & Johnson's Investor Webcast. (Operator Instructions) This call is being recorded. If anyone has any objections, you may disconnect at this time. (Operator Instructions) I would now like to turn the conference call over to Johnson & Johnson. You may begin.

Christopher DelOrefice
Johnson & Johnson - VP of IR

Good morning. This is Chris DelOrefice, Vice President of Investor Relations for Johnson & Johnson. Welcome to this webcast as we are pleased to review our Phase III ENSEMBLE study results of our investigational single-dose COVID-19 vaccine candidate. Joining me on today's call is Mathai Mammen, Global Head of Janssen Research and Development.

A few logistics before we get into the details. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. This webcast may contain forward-looking statements, including statements about our investigational single-dose COVID-19 vaccine candidate. The viewer is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot